Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

DI MARCO, Vito
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.092
EU - Europa 5.611
AS - Asia 2.379
AF - Africa 57
SA - Sud America 16
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 10
Totale 25.175
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.056
IT - Italia 1.848
CN - Cina 1.247
FI - Finlandia 1.097
SG - Singapore 820
UA - Ucraina 761
IE - Irlanda 416
DE - Germania 399
GB - Regno Unito 338
RU - Federazione Russa 197
SE - Svezia 178
RO - Romania 92
FR - Francia 83
BE - Belgio 75
IN - India 74
TR - Turchia 60
KR - Corea 52
CI - Costa d'Avorio 46
HK - Hong Kong 41
CA - Canada 31
CZ - Repubblica Ceca 28
IR - Iran 26
NL - Olanda 24
CH - Svizzera 15
PL - Polonia 12
GR - Grecia 11
JP - Giappone 11
AT - Austria 10
AU - Australia 9
ES - Italia 8
EU - Europa 8
UZ - Uzbekistan 8
BR - Brasile 6
LB - Libano 6
SA - Arabia Saudita 6
BG - Bulgaria 5
EG - Egitto 5
ID - Indonesia 4
MY - Malesia 4
VE - Venezuela 4
MM - Myanmar 3
MX - Messico 3
NG - Nigeria 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CU - Cuba 2
DK - Danimarca 2
EC - Ecuador 2
GH - Ghana 2
IL - Israele 2
IQ - Iraq 2
NO - Norvegia 2
PE - Perù 2
PT - Portogallo 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CL - Cile 1
CM - Camerun 1
CO - Colombia 1
EE - Estonia 1
GE - Georgia 1
IS - Islanda 1
JO - Giordania 1
LK - Sri Lanka 1
LT - Lituania 1
MC - Monaco 1
MD - Moldavia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
RS - Serbia 1
Totale 25.175
Salva come PNG Salva come JPEG
Città #
Fairfield 2.836
Ashburn 1.566
Woodbridge 1.436
Chandler 1.310
Houston 1.129
Wilmington 1.129
Seattle 1.083
Cambridge 992
Ann Arbor 867
Singapore 679
Palermo 489
Dublin 414
Jacksonville 414
Medford 397
Des Moines 326
Altamura 286
Nanjing 263
Princeton 252
Lawrence 213
San Diego 181
Boardman 152
New York 121
Beijing 113
Tulsa 109
Santa Clara 107
Shenyang 97
Dearborn 82
Jinan 72
Brussels 70
Nanchang 70
Milan 67
Changsha 62
Jiaxing 61
Ludwigshafen am Rhein 61
Hebei 60
Tianjin 58
London 57
Izmir 54
Abidjan 46
Falls Church 45
Zhengzhou 45
Los Angeles 42
Saint Petersburg 41
Kumar 40
San Paolo di Civitate 39
Ningbo 36
Seongnam 36
Phoenix 33
Helsinki 28
Guangzhou 26
Redwood City 26
Verona 26
Ottawa 25
Bremen 24
Taizhou 24
Auburn Hills 23
Brno 23
Lanzhou 23
Rome 23
San Mateo 23
Venice 22
Hangzhou 20
Orange 19
Columbus 18
Hong Kong 18
Kunming 18
Washington 17
Munich 16
Tehran 16
Pune 15
Fuzhou 14
Kilburn 14
Norwalk 14
Düsseldorf 13
Central 12
Chicago 11
Hounslow 11
Redmond 11
Tappahannock 11
Hefei 10
Indiana 10
Napoli 10
Central District 9
Dallas 9
Lappeenranta 9
Seoul 9
Taiyuan 9
Atlanta 8
Haikou 8
Lake Forest 8
Moscow 8
Shanghai 8
Chiswick 7
Edinburgh 7
Aragona 6
Den Haag 6
Hanover 6
Mehlingen 6
Mussomeli 6
Padova 6
Totale 18.887
Salva come PNG Salva come JPEG
Nome #
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 202
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 200
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 199
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 191
Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. 190
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 187
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 186
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 185
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin 178
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 177
Breaking bad news: How to cope 177
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 176
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 174
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 174
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 171
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 170
Targeted Therapies in Hepatocellular Carcinoma 163
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated amplification assay 161
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 158
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 156
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 155
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 153
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 153
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 153
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 152
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 152
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 151
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 151
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 150
Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy. 148
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 147
Adefovir for lamivudine resistant HBV: More than meets the eye. 147
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 146
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 146
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 145
STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD 144
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 144
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 144
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 143
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 142
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 141
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 140
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 140
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 140
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 140
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 139
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 138
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 138
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 137
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 137
Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. 137
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 137
Halitosis: could it be more than mere bad breath? 136
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 136
Chronic hepatitis B: who to treat and which choice of treatment? 135
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 135
Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. 135
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 133
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. 132
A patient with acute hepatitis C and possible IFN toxicity [2] 132
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 132
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 131
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients 131
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. 131
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 130
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 130
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 130
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C 129
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 129
Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial 128
Hepatic expression of cyclooxygenase-2 in non alcoholic fatty liver disease 128
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 128
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C 128
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. 128
Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials 127
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 127
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values 127
Hyperferritinemia is a risk factor for steatosis in chronic liver disease. 127
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 126
Liver disease in chelated transfusion-dependent thalassemics: the role of iron and chronic hepatitis C 126
The presence of White Matter Lesions is not associated with Non-alcoholic Fatty Liver Disease but with its histological severity 126
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 125
HCV clearance among hemophiliacs and beta-thalassemics 124
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 124
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 124
Impact of HBV genotypes A and D genetic variability on infection evolution 122
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 122
Sorafenib: from literature to clinical practice 121
Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD 121
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy 120
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 120
TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. 120
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study 120
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 119
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease 119
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 118
Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model 118
Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. 117
Insulin resistance is associated with steatosis in non-diabetic patients with genotype 1 chronic hepatitis C 117
Mortality in patients with hepatocellular carcinoma predicted by six scoring: none is the winner 116
Totale 14.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.933
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.933
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.956 0 0 0 0 0 851 751 505 743 353 546 207
2020/20213.672 216 319 207 356 297 155 206 260 476 478 339 363
2021/20223.089 137 661 128 95 107 134 172 165 380 372 226 512
2022/20233.949 391 838 51 419 413 626 274 264 426 17 155 75
2023/20241.556 76 244 106 116 132 389 145 86 22 38 12 190
2024/20251.369 107 290 217 425 155 175 0 0 0 0 0 0
Totale 26.308